Hirotake Tsukamoto
Kyoto, 6068501, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome.
Journal: Cancer immunology, immunotherapy : CII
Published: December 03, 2025
Effect of organism aging on the development of anti-PD-(L)1 therapy-associated adverse events.
Journal: Immunological medicine
Published: October 01, 2025
ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4+ and CD8+ T-cell responses and neutralizing antibody induction.
Journal: Journal of virology
Published: April 15, 2025
Beneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy.
Journal: International immunology
Published: November 19, 2024
ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis.
Journal: JCI insight
Published: September 16, 2024
Anti-arthritic effects of polyunsaturated fatty acid-rich supplementation combined with selective soluble epoxide hydrolase inhibitors in a collagen-induced arthritis mouse model.
Journal: Modern rheumatology
Published: September 05, 2024
Corrigendum to "Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells" [Neoplasia 39 (2023), 100893].
Journal: Neoplasia (New York, N.Y.)
Published: June 29, 2024
Age-associated reduction of sinus macrophages in human mesenteric lymph nodes.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: March 10, 2024
Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations.
Journal: Cancers
Published: December 01, 2023
Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.
Journal: Microbiology and immunology
Published: January 03, 2023
Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells.
Journal: Neoplasia (New York, N.Y.)
Published: November 24, 2022
Last Updated: 09/26/2026